Literature DB >> 452621

Pathogenesis and therapy of liver disease in protoporphyria.

J R Bloomer.   

Abstract

Protoporphyria is an inherited disorder in man characterized by the overproduction of protoporphyrin, a compound that is excreted by the liver. Hepatobiliary disease may occur in protoporphyria, and several cases have been reported in which death was due to liver disease. Based on the histological evaluation of liver biopsy specimens from 18 patients, 6 of whom died with cirrhosis and liver failure, we speculate that liver disease in this condition is caused by protoporphyrin deposits in hepatobiliary structures. These deposits are composed of crystals and have a characteristic birefringence when examined by polarization microscopy.One patient with early liver damage was given cholestyramine and vitamin E in an attempt to reduce the amount of protoporphyrin which the liver excreted daily. Liver function tests returned to normal, and red cell and plasma protoporphyrin levels decreased. A repeat liver biopsy after one year of therapy showed healing, with decrease of the protoporphyrin deposits.Liver disease in protoporphyria may be treated by directing therapy toward the metabolic abnormality.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 452621      PMCID: PMC2595712     

Source DB:  PubMed          Journal:  Yale J Biol Med        ISSN: 0044-0086


  34 in total

1.  CONGENITAL ERYTHROPOIETIC PROTOPORPHYRIA. I. CASE REPORTS, CLINICAL STUDIES AND PORPHYRIN ANALYSES IN TWO BROTHERS.

Authors:  F S PORTER; B A LOWE
Journal:  Blood       Date:  1963-11       Impact factor: 22.113

2.  Erythropoietic protoporphyria. 10 years experience.

Authors:  V A DeLeo; M Poh-Fitzpatrick; M Mathews-Roth; L C Harber
Journal:  Am J Med       Date:  1976-01       Impact factor: 4.965

3.  Reduced ferrochelatase activity: a defect common to porphyria variegata and protoporphyria.

Authors:  D M Becker; J D Viljoen; J Katz; S Kramer
Journal:  Br J Haematol       Date:  1977-06       Impact factor: 6.998

4.  Study of factors causing excess protoporphyrin accumulation in cultured skin fibroblasts from patients with protoporphyria.

Authors:  J R Bloomer; D A Brenner; M J Mahoney
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

5.  A simple micro method for the direct determination of delta-amino (14C) levulinic acid production in murine spleen and liver homogenates.

Authors:  P S Ebert; D P Tschudy; J N Choudhry; M A Chirigos
Journal:  Biochim Biophys Acta       Date:  1970-05-12

6.  Erythropoietic protoporphyria: juvenile protoporphyrin hepatopathy cirrhosis and death.

Authors:  D J Cripps; L A Gilbert; S S Goldfarb
Journal:  J Pediatr       Date:  1977-11       Impact factor: 4.406

7.  Human hepatic delta-aminolaevulinate synthase: requirement of an exogenous system for succinyl-coenzyme A generation to demonstrate increased activity in cirrhotic and anticonvulsant-treated subjects.

Authors:  H L Bonkowsky; J S Pomeroy
Journal:  Clin Sci Mol Med       Date:  1977-05

8.  The hepatic lesion in protoporphyria (PP): preliminary studies of haem metabolism, liver structure and ultrastructure.

Authors:  N R Pimstone; B L Webber; G H Blekkenhorst; L Eales
Journal:  Ann Clin Res       Date:  1976

9.  Heme synthetase deficiency in human protoporphyria. Demonstration of the defect in liver and cultured skin fibroblasts.

Authors:  H L Bonkowsky; J R Bloomer; P S Ebert; M J Mahoney
Journal:  J Clin Invest       Date:  1975-11       Impact factor: 14.808

10.  Hepatic failure and death from erythropoietic protoporphyria.

Authors:  J A Singer; A G Plaut; M M Kaplan
Journal:  Gastroenterology       Date:  1978-03       Impact factor: 22.682

View more
  10 in total

1.  The diagnosis and management of erythropoietic protoporphyria.

Authors:  Manish Thapar; Herbert L Bonkovsky
Journal:  Gastroenterol Hepatol (N Y)       Date:  2008-08

Review 2.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Postgrad Med J       Date:  2007-12       Impact factor: 2.401

Review 3.  Liver disease in erythropoietic protoporphyria: insights and implications for management.

Authors:  A V Anstey; R J Hift
Journal:  Gut       Date:  2007-03-14       Impact factor: 23.059

4.  Molecular defects in ferrochelatase in patients with protoporphyria requiring liver transplantation.

Authors:  J Bloomer; C Bruzzone; L Zhu; Y Scarlett; S Magness; D Brenner
Journal:  J Clin Invest       Date:  1998-07-01       Impact factor: 14.808

5.  Protoporphyrin hepatopathy. Effects of cholic acid ingestion in murine griseofulvin-induced protoporphyria.

Authors:  M B Poh-Fitzpatrick; J A Sklar; C Goldsman; J H Lefkowitch
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

6.  Protoporphyrin-induced cholestasis in the isolated in situ perfused rat liver.

Authors:  D L Avner; R G Lee; M M Berenson
Journal:  J Clin Invest       Date:  1981-02       Impact factor: 14.808

7.  Erythropoietic Protoporphyria-related Hepatopathy Successfully Treated with Phlebotomy.

Authors:  Akihiro Yoshida; Satoru Hagiwara; Tomohiro Watanabe; Naoshi Nishida; Hiroshi Ida; Toshiharu Sakurai; Yoriaki Komeda; Kentaro Yamao; Mamoru Takenaka; Eisuke Enoki; Masatomo Kimura; Masako Miyake; Akira Kawada; Masatoshi Kudo
Journal:  Intern Med       Date:  2018-09-01       Impact factor: 1.271

8.  Role of phlebotomy in the treatment of liver damage related to erythropoietic porphyria.

Authors:  Satoru Hagiwara; Naoshi Nishida; Hiroshi Ida; Kazuomi Ueshima; Yasunori Minami; Masahiro Takita; Tomoko Aoki; Masahiro Morita; Hirokazu Chishina; Yoriaki Komeda; Akihiro Yoshida; Ah-Mee Park; Masako Sato; Akira Kawada; Hajime Nakano; Hiroshi Nakagawa; Masatoshi Kudo
Journal:  Sci Rep       Date:  2022-04-12       Impact factor: 4.379

Review 9.  Comparison of human and bovine protoporphyria.

Authors:  D A Brenner; J R Bloomer
Journal:  Yale J Biol Med       Date:  1979 Sep-Oct

Review 10.  An overview of the cutaneous porphyrias.

Authors:  Robert Dawe
Journal:  F1000Res       Date:  2017-10-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.